Videos

Jeffrey Bratberg, PharmD, FAPhA, leads discussion tackling common opioid-related misconceptions as well as unintended consequences of the opioid crisis.

Jeremy Adler, DMSc, PA-C, DFAAPA, leads discussion on elements that negatively impacts the quality of care for patients requiring pain management.

A panel of experts in the management of NETs discuss the role of peptide receptor radionuclide therapy for NETs.

Pharmacy Times® interviewed Beth Battaglino, RN-C, CEO of HealthyWomen and a convener of the COVID-19 Vaccine Education and Equity Project, on the recent “Count Me In” digital campaign.

Robert Mancini, PharmD, BCOP, FHOPA, of St. Luke’s Cancer Institute: Boise, comments on his experience navigating challenges using belantamab mafodotin, an anti-BCMA therapy, to treat relapsed/refractory multiple myeloma.

Recommendations for managing patients who receive belantamab mafodotin, an anti-BCMA therapy, for relapsed/refractory multiple myeloma, with special considerations regarding the ocular health of patients.

Following the establishment of the Federal Retail Pharmacy Program by the CDC, a panel of experts sat down with Pharmacy Times® to address the implications of the Federal Retail Pharmacy Program for COVID-19 vaccinations.

Experts in the management of VTE discuss the deterrents among providers, patients, and pharmacists, specifically looking at the various dosage forms of treatment.

A panel of experts discuss the risks vs benefits of prophylactic care for patients to prevent VTE.

Best practices for prescribing an immunomodulatory-based therapy or a proteasome inhibitor as treatment for relapsed/refractory multiple myeloma.

Considerations for treating patients with relapsed/refractory multiple myeloma with elotuzumab, daratumumab, or isatuximab based on more recent clinical trial data and differences between each treatment option.

Variables considered by healthcare professionals when selecting an appropriate backbone regimen to manage a patient with relapsed or refractory multiple myeloma.

Healthcare stakeholders comment on current practices managing patients with relapsed/refractory multiple myeloma during the COVID pandemic and discuss their comfort switching patients over from intravenous daratumumab to subcutaneous daratumumab.

Factors that influence treatment selection for relapsed or refractory multiple myeloma, and suggestions to help streamline decision making and address limitations associated with current treatment pathways.

A historical review of treatment advances in relapsed/refractory multiple myeloma and criteria used to define relapsed or refractory disease.

Danielle DiBari, the chief pharmacy officer and senior vice president of business operations for NYC Health + Hospitals, discusses some of the challenges involved in coordinating vaccine distribution across New York’s public health system.

Dwight Kloth, PharmD, FCCP, BCOP, director of pharmacy at Fox Chase Cancer Center, discusses the role of the oncology pharmacist in the cancer care continuum, and how this role has been impacted by the COVID-19 pandemic.

Chad Landmon, JD, chair of intellectual property and FDA practice groups at Axinn, Veltrop & Harkrider, discusses how the COVID-19 pandemic has impacted the FDA’s approval process.

Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, discuss the management of stomatitis caused by everolimus when used for NETs.

Cecilia Lau, RPh, BCOP, APh, reviews the efficacy and safety data for everolimus in the treatment of NETs.

Megan May, PharmD, BCOP, and Daneng Li, MD, discuss the availability of home-injection programs for patients with NETs, especially during the coronavirus pandemic.

Experts in the management of NETs review the various delivery systems and preparations available for short- and long-acting somatostatin analogues.

Megan May, PharmD, BCOP, and Cecilia Lau, RPh, BCOP, APh, discuss the pharmacists’ role in choosing the treatment plan for patients with NETs.

The panel of experts discuss how they choose 1 somatostatin analogue over another and the factors to consider in the management of NETs.

Cecilia Lau, RPh, BCOP, APh, and Daneng Li, MD, review the differences among the somatostatin analogues, particularly the differences in PK data.

The panel of experts in the management of NETs review the indications and safety data of the somatostatin analogues.

Megan May, PharmD, BCOP, and Daneng Li, MD, review the efficacy and the pivotal trials for the somatostatin analogues in the treatment of NETs.

Experts in the management of NETs discuss how the treatment landscape has evolved.

Megan May, PharmD, BCOP, and Daneng Li, MD, discuss when patients with NETs should be considered for active surveillance vs treatment.

A panel of experts in neuroendocrine tumors provide a definition of the disease and the diagnosis methods.